Study Identifies Improved Carfilzomib Dosing Strategy for Relapsed/Refractory Multiple Myeloma
In the phase 3 ARROW study of carfilzomib (Kyprolis) in adults with relapsed or refractory multiple myeloma, once-weekly dosing was associated with significantly longer progression-free survival (PFS) than twice-weekly dosing (hazard ratio, 0.69; 95% CI, 0.54-0.83); P = .0029). Median PFS was 11.2 months (95% CI, 8.6-13.0 mo) in the once-weekly group (n = 240) versus 7.6 months (95% CI, 5.8-9.2 mo) in the twice-weekly group (n = 238). Once-weekly dosing was also associated with lower rates of grade 3 or worse cardiac failure. The findings led trial-sponsor Amgen to file a supplemental New Drug Application with the FDA in August to include a once-weekly dosing option in the prescribing information for Kyprolis.
Read more here.
Reference
Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018l;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Erratum in: Lancet Oncol. 2018;19(8):e382.
